Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELI: Pembrolizumab with IRE and CaEP in pMMR Metastatic Colorectal Cancer
NCT05609656Phase 2Terminated
- Start
- Jan 2023
- Primary completion
- Apr 2024
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in colorectal cancer (metastatic) (mCRC). Started Jan 2023; status: terminated.
02
Drugs
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT05609656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609656.